Real-Time Identity Analytics and Federated Trust Combine Security, Low Total Cost of Ownership and Optimal User Experience

San Jose, Calif. – February 20, 2014 – ThreatMetrix™, the fastest-growing provider of context-based security and advanced fraud prevention solutions, today announced a revolutionary offering that improves the security associated with traditional username and password protection for accessing enterprise applications in conjunction with the upcoming RSA Conference 2014, February 24-28 at Moscone Center, San Francisco.

With the advent of bring-your-own-device (BYOD) and cloud-based applications, today’s enterprise security professionals are challenged with augmenting the application access security that can be obtained through simple username and password verification and cumbersome two-factor authentication with minimal impact to the user experience.

“No enterprise wants to be called out for falling victim to a data breach, as it erodes trust,” said Reed Taussig, president and CEO, ThreatMetrix. “However, if enterprises implement time consuming authentication techniques, this will erode overall productivity and motivate the workforce to find ways around the authentication. This is where frictionless context-based authentication comes into play, which establishes trust for each account login based on fully anonymous user identity, device usage, geolocation, behavior and other factors without compromising consumer identity or workforce efficiency.”

Gartner estimates that by year end 2016, more than 30 percent of enterprises will use contextual authentication for remote workforce access. [Source: Gartner Magic Quadrant for User Authentication, December, 2013]

Overall, context-based authentication offers three essential benefits to enterprises. These include:

• Frictionless access – Real-time, passive assessment of the login context through frictionless two-factor authentication enables businesses to streamline access for known and trusted combinations of accounts and devices – reducing effort and inconvenience for the workforce by not requiring additional one-time passwords for each login.

• Increased security – Combining global federated trust identities with context-based authentication enables businesses to quickly and easily identify high-risk connections that have the potential to compromise corporate IP and valuable data. High-risk connections include devices that are part of botnets, use of spoofed and compromised identities or devices that are known to be involved with fraudulent access across the ThreatMetrix™ Global Trust Intelligence Network (The Network).

• Operational Efficiency – Real-time API-driven big data analytics means actionable intelligence at the point of control, rather than information being stored in a data warehouse.

“Enterprise adaptive access control combines contextual information and user credentials to evaluate the risk of users attempting to access resources. Once the purview of e-commerce and financial services, adaptive access is finding an increased role in workforce identity — particularly for mobile device use cases.” [Source: “Adaptive Access Control Brings Together Identity, Risk and Context,” Gartner: Trent Henry, August 2013]

ThreatMetrix is uniquely positioned to provide one of the most powerful context-based authentication and fraud prevention solutions on the market. The solution leverages the vast amount of data in The Network, one of the largest fully anonymized global identity and fraud networks in the world. Through The Network, ThreatMetrix protects more than 160 million active user accounts, 2,500 customers and 10,000 websites.

“All ThreatMetrix customers benefit from anonymized shared identity and threat data worldwide across The Network, increasing the quality and value of the data as The Network grows,” said Taussig. “Due to shared data on The Network, in the United States, for example, we have an 80 percent recognition rate for users attempting an account login. This means that for four in five logins, ThreatMetrix recognizes at least one anonymized data point from previous activity in The Network – such as the email address, telephone number or account name. This offers enterprises and other businesses a full 360 degree assessment of a user’s risk to more accurately differentiate between hackers and valid workforce access.”

Federating identities without federating trust creates many opportunities for cybercrime. Combining context-based authentication and a global federated identity network is the most efficient and cost effective way for enterprises to reduce the threat of data breaches from unauthorized application access, eliminating employee friction. This includes protection against both internal and external threats, since enterprises now face risks from employees who jeopardize regulatory compliance through unauthorized password sharing and other risky behaviors.

In addition to its evolution as a context-based authentication provider for enterprises, ThreatMetrix continues to build trust on the Internet by protecting businesses across industries, including financial services, e-commerce, payments, social networks, government agencies and social networks, through advanced online fraud prevention. This solution offers protection against threats including account takeover, payment fraud, fraudulent account registration and multi-channel Web fraud.

To learn more about ThreatMetrix’s context-based authentication and advanced fraud solutions, stop by booth 232 in the South Expo at RSA Conference 2014. During the conference, ThreatMetrix is also a proud sponsor of the Alta Associate’s Executive Women’s Forum Reception, which takes place Wednesday, February 26, 7-9 p.m. at the W Hotel in San Francisco.

About ThreatMetrix

ThreatMetrix builds trust on the Internet by offering market-leading advanced fraud prevention and frictionless context-based security solutions. These solutions authenticate consumer and workforce access to mission critical applications using real-time identity and access analytics that leverage the world’s largest trusted identity network.

ThreatMetrix secures enterprise applications against account takeover, payment fraud, fraudulent account registrations, malware, and data breaches. Underpinning the solution is the ThreatMetrix™ Global Trust Intelligence Network, which analyzes over 500 million monthly transactions and protects more than 160 million active user accounts across 2,500 customers and 10,000 websites.

The ThreatMetrix solution is deployed across a variety of industries, including financial services, enterprise, e-commerce, payments, social networks, government and insurance.

For more information, visit www.threatmetrix.com or call 1-408-200-5755.

Join the cybersecurity conversation by visiting the ThreatMetrix blog, Facebook, LinkedIn and Twitter pages.

ThreatMetrix Leads the Industry in “Building Trust on the Internet” to Reduce Fraud and Facilitate Fast and Frictionless Online Transactions

San Jose, CA – January 29, 2014 – ThreatMetrix™, the fastest growing provider of context-based authentication and advanced Web fraud prevention solutions, today announced a compilation of record 2013 milestones and its emergence as one of the largest fully anonymized global identity and fraud networks in the world.

In 2013, the rules governing global cybercrime protection changed. Global governments now assign more importance to individual consumer privacy than to the rapidly increasing financial losses online retailers, enterprises and financial institutions face at the hands of highly sophisticated global cybercriminals.

“We work with many of the world’s most recognized and trusted brands, financial institutions, enterprises and government agencies,” said Reed Taussig, president and CEO, ThreatMetrix. “Today, we protect over 500 million transactions each month and over 160 million active online accounts. Every transaction is screened by ThreatMetrix to provide businesses with confidence and trust that they are servicing an authenticated and valuable customer and not a cybercriminal. The ThreatMetrix™ Global Trust Intelligence Network (The Network), which is completely passive and fully consumer anonymized, has proven to be the right solution to satisfy the competing agendas of consumer privacy and security.”

During 2013, ThreatMetrix made several significant advances in key areas, including:

• Company Evolution: In 2013, ThreatMetrix completed its evolution from an advanced device identification and malware detection company to a true platform provider. “Our unique combination of technologies, processes and data significantly broadens the scope of the ThreatMetrix solution in the online world,” said Taussig. “We enable a new kind of passive, context-based authentication that can establish credibility of each transaction based on fully anonymous device usage, purchase history and other factors to determine the level of authentication required to process the request without risk of compromising consumer identity.”
• The Network: In 2013, ThreatMetrix expanded The Network – a repository of devices, anonymized identities, transactions and interactions – to include over 2,500 customers and 10,000 websites, enabling ThreatMetrix customers to query transactions in real-time to differentiate between legitimate customers and cybercriminals hiding behind spoofed or stolen identities.
• The Rise of Mobile: Mobile traffic on The Network increased threefold and represented a third of all network traffic in 2013. ThreatMetrix projects mobile traffic to represent at least 50 percent of its network traffic in 2014.
• Record Transaction Volume: ThreatMetrix more than doubled the number of customer transactions it processed in 2013, reaching 4.4 billion transactions during 2013. Transaction volume is anticipated to jump to more than 20 billion transactions in 2014, underscoring ThreatMetrix’s rapid growth and corresponding systems performance and reliability.
• Record Recurring Revenue: The company’s recurring customer revenue in 2013 was more than 120 percent total revenues in 2012, which is a testament to the success ThreatMetrix customers are experiencing with its products.
• SaaS Recurring Revenue Model: ThreatMetrix’s financial performance has been outstanding, driven in large part by customer retention approaching 100 percent. With a predictable revenue stream, ThreatMetrix will have the ability to sustain investments in new products and services to better service existing customers as well as expansion into new markets.
• New Customers: The company more than doubled its customer base in 2013, both directly and in conjunction with its extensive partner channel. The average new account value of these customers was up almost 100 percent over 2012.
• New Products and Technologies: ThreatMetrix launched several breakthrough products and technologies in 2013. By combining the power of ThreatMetrix™ Persona ID, ThreatMetrix™ Trust Tags and the ThreatMetrix™ Global Policy Engine, the company now enables its customers to define, validate and compare industry standard best practices and techniques to passively identify and authenticate good customers while simultaneously stopping sophisticated international cybercriminals. ThreatMetrix Trust Tags are truly unique in the industry, enabling customers to anonymously interrogate and validate credentials and past behaviors in order to eliminate costly, intrusive step-up authentications while simultaneously preventing cybercrime.
• International Growth: Asia Pacific business doubled year-over-year in 2013 and similar growth opportunities are projected in 2014.
• New and Existing Markets: ThreatMetrix doubled its presence in the financial services market year-over-year while becoming the defacto fraud solution in the retail payments space. Meanwhile, ThreatMetrix entered the insurance and healthcare markets.
• Operations: In response to triple digit growth in transaction volume during 2013, the company tripled the capacity of its data centers in California, Florida and the Netherlands.
• Strategic Management Hires: John Lindner joined as vice president of sales, Americas and Dr. Stephen Topliss was named vice president of services and support.
• ThreatMetrix 2013 Cybercrime Prevention Summit: Themed “Strength in Numbers” and keynoted by Brian Krebs, author of KrebsOnSecurity.com, the third annual sold-out summit emphasized the importance of a collective approach to stopping sophisticated cybercriminals in their tracks, meaning that individuals and businesses must work together to make cybersecurity a priority to stay ahead of today’s evolving cybercrime threats.
• Awards: ThreatMetrix won several industry awards, including 2013 Best in Biz Award; Security Innovation Network (SINET) 16 Innovators list; 2013 American Business Award Gold Stevie for the “Best New Product or Service of the Year – Software – Security Solution” and a Silver Stevie for the “Most Innovative Tech Company of the Year”; 2013 TechNavio Top 15 Cloud Security Company; 2013 Gold for “Most Innovative Company of the Year” in Best in Biz Awards 2013 International; 2013 AlwaysOn Global Top 250 Private Companies List and The 15 Most Important Security Startups of 2013 by Business Insider.

“ThreatMetrix exited 2013 leading the way towards building trust on the Internet by helping its customers identify and differentiate between authenticated good consumers and bad actors with its TrustDefender™ Cybercrime Protection Platform,” said Taussig. “By leveraging the power of The Network, now one of the largest fully anonymized fraud identification networks in the world, ThreatMetrix protects customer trust and eliminates fraud without compromising consumer privacy. Our record 2013 milestones position the company for continued growth throughout 2014.”

To learn more about “The New Model for Building Trust on the Internet,” read the latest ThreatMetrix blog post by Taussig.

About ThreatMetrix

ThreatMetrix secures Web transactions against account takeover, payment fraud, identity spoofing, malware, and data breaches. The ThreatMetrix Global Trust Intelligence Network, which analyzes 500 million monthly transactions, provides context-based authentication and Web fraud prevention to help companies accelerate revenue, reduce costs and eliminate friction. ThreatMetrix protects ThreatMetrix protects more than 160 million active user accounts, 2,500 customers and 10,000 websites across a variety of industries, including financial services, enterprise, e-commerce, payments, social networks, government, and insurance. For more information, visit www.threatmetrix.com or call 1-408-200-5755.

Join the cybersecurity conversation by visiting the ThreatMetrix blog, Facebook, LinkedIn and Twitter pages.

Minnesota, United States and Melbourne, Australia – January 7, 2014 – Osprey Medical Inc. (ASX: OSP) today
announced enrollment of the first patient in the AVERT IDE Clinical Study. The patient was enrolled at Harbor UCLA
Medical Center in Torrance, California by Dr William French. This trial will evaluate the Company’s AVERT™ System
for a marketing claim expansion to include “reduction of Contrast Induced Nephropathy (CIN)” for patients
undergoing angiogram or stenting procedures.

The randomized, multi-center, IDE trial will be enrolling approximately 700 patients at up to 45 sites in the U.S.,
Canada, Europe, Australia, and New Zealand. In addition to evaluating the effectiveness of the AVERT System for
CIN reduction, the trial will include a health economics sub-study to evaluate the potential benefits for patients,
hospitals, and payers.

Study Investigator at Harbor UCLA, Dr William French, stated: “We are excited to be involved in the AVERT Study to
evaluate the reduction of contrast used in our interventional cardiology procedures and to protect the kidneys of
patients at risk for CIN”. Mike McCormick, President and CEO of Osprey Medical, commented: “The enrollment of
our first patient into the AVERT Trial is a significant corporate milestone for us. We anticipate the pace of site
activation and patient enrollment will accelerate throughout 2014.”

Further information is available at www.ospreymed.com on the “Clinical” page.

About the AVERT™ System

The Avert System consists of a re-usable contrast modulator with easy to adjust settings. A disposable modulation reservoir
easily loads into the contrast modulator unit and attaches to commonly used manual injection systems used by interventional
cardiologists during heart procedures.

About the AVERT Trial

The aim of the trial is to support expansion of the AVERT System’s marketing claim to include “reduction of contrast induced
nephropathy (CIN)”. Patients who are at-risk for CIN with pre-existing stage 3-4 chronic kidney disease undergoing a heart
procedure such as angioplasty and stenting may be eligible to participate in the trial. The trial will enroll approximately 700
patients at up to 45 sites in the U.S., Europe, Canada, Australia, and New Zealand. The Company is aiming to complete
enrollment, submit for and obtain FDA clearance for the expanded claim in the first half of 2015.

About Osprey Medical

Osprey Medical’s core technologies originated from research conducted by Dr David Kaye at Melbourne’s Baker IDI Heart and
Diabetes Institute. Osprey is focused on improving patients’ quality of life by protecting those with chronic kidney disease from
contrast induced nephropathy (CIN) and preventing limb amputation in diabetic patients with advanced foot infections. The
Company’s primary product, the AVERT™ System, is designed to reduce the amount of dye (contrast) injected during commonly
performed heart procedures, thus protecting kidneys from damaged known as contrast induced nephropathy (CIN). Osprey
Medical’s Limb Recovery™ System is a percutaneous technology that allows physicians to deliver targeted doses of antibiotics to
the lower limb in patients with diabetes suffering from advanced foot infections.

Osprey Medical’s Board and Management are comprised of experienced and successful personnel with established track records
covering medical device development, regulatory approvals, sales and marketing, and mergers-acquisitions. Osprey Medical’s
advisory board comprises world-recognised experts in heart and kidney diseases.

Contact details:
Media
Haley Price
Buchan Consulting
T: (613) 986 64772
M: (61) 423 139 163
Investors
Rebecca Wilson
Buchan Consulting
M: (61) 417 382 391
Company
Doug Schoenberg
VP of Marketing
T: (952) 955 8230

Minnesota, United States and Melbourne, Australia – January 2, 2014 – Osprey Medical Inc. (ASX: OSP) today

announced publication of results from the pilot clinical trial of the AVERT system (Contrast Conservation
System/CCS). The study which was conducted in late 2012 at the Alfred Hospital in Melbourne Australia by Dr David
Kaye and Dr Stephen Duffy, was titled “Reducing iodinated contrast volume by manipulating injection pressure
during coronary angiography” and was published ahead of press on-line in the December 2013 edition of leading
industry peer-reviewed journal “Catheterization and Cardiovascular Interventions”.
The 21-patient pilot clinical trial, demonstrated that the use of the AVERT System was associated with a highly
significant 40% reduction in dye injection compared with standard imaging techniques, whilst maintaining image
quality. Study investigator, Dr David Kaye Head, Cardiology Division Baker IDI Heart and Diabetes Institute stated:
“We are very encouraged by the effectiveness of the AVERT System in reducing the amount of contrast dye used in
interventional cardiology procedures while maintaining acceptable visualization of the coronary anatomy. The
AVERT System offers physicians the opportunity to lower contrast dye usage which may ultimately protect the
kidneys of the many patients who are at risk for CIN”.
Mike McCormick, President and CEO of Osprey Medical, commented: “Successfully driving physician awareness via
leading industry peer reviewed scientific publications by key opinion leading physicians such as Dr Kaye and Dr Duffy,
is expected to be of great assistance to the commercialisation of AVERT System. We look forward to publication of
additional tier one scientific data of the AVERT System in the future.
We are currently underway with a randomized, multi-center, IDE trial of the AVERT System, with first patient
enrolment imminent. In addition to evaluating the effectiveness of the AVERT System for CIN reduction, the trial will
also measure economics savings with use of the AVERT System.”
Further information:

About the AVERT™ System
The Avert System consists of a re-usable contrast modulator with easy to adjust settings. A disposable modulation reservoir
easily loads into the contrast modulator unit and attaches to commonly used manual injection systems used by interventional
cardiologists during heart procedures.

About the AVERT Trial
The aim of the trial is to support expansion of the AVERT System’s marketing claim to include “reduction of contrast induced
nephropathy (CIN)”. Patients who are at-risk for CIN with pre-existing stage 3-4 chronic kidney disease undergoing a heart
procedure such as angioplasty and stenting may be eligible to participate in the trial. The trial will enroll approximately 700
patients at up to 45 sites in the U.S., Europe, Canada, Australia, and New Zealand. The Company is aiming to complete
enrollment, submit for and obtain FDA clearance for the expanded claim in the first half of 2015. Further information is
available at www.ospreymed.com on the “Clinical” page.

About Osprey Medical
Osprey Medical’s core technologies originated from research conducted by Dr. David Kaye at Melbourne’s Baker IDI Heart and
Diabetes Institute. Osprey is focused on improving patients’ quality of life by protecting those with chronic kidney disease from
contrast induced nephropathy (CIN) and preventing limb amputation in diabetic patients with advanced foot infections. The
Company’s primary product, the AVERT™ System, is designed to reduce the amount of dye (contrast) injected during commonly
performed heart procedures, thus protecting kidneys from damaged known as contrast induced nephropathy (CIN). Osprey
Medical’s Limb Recovery™ System is a percutaneous technology that allows physicians to deliver targeted doses of antibiotics to
the lower limb in patients with diabetes suffering from advanced foot infections.

Osprey Medical’s Board and Management are comprised of experienced and successful personnel with established track records
covering medical device development, regulatory approvals, sales and marketing, and mergers-acquisitions. Osprey Medical’s
advisory board comprises world-recognised experts in heart and kidney diseases

Minnesota, United States and Melbourne, Australia – January 2, 2014 – Osprey Medical Inc. (ASX: OSP) today announced publication of results from the pilot clinical trial of the AVERT system (Contrast Conservation System/CCS). The study which was conducted in late 2012 at the Alfred Hospital in Melbourne Australia by Dr David Kaye and Dr Stephen Duffy, was titled “Reducing iodinated contrast volume by manipulating injection pressure during coronary angiography” and was published ahead of press on-line in the December 2013 edition of leading industry peer-reviewed journal “Catheterization and Cardiovascular Interventions”.

The 21-patient pilot clinical trial, demonstrated that the use of the AVERT System was associated with a highly significant 40% reduction in dye injection compared with standard imaging techniques, whilst maintaining image quality. Study investigator, Dr David Kaye Head, Cardiology Division Baker IDI Heart and Diabetes Institute stated: “We are very encouraged by the effectiveness of the AVERT System in reducing the amount of contrast dye used in interventional cardiology procedures while maintaining acceptable visualization of the coronary anatomy. The AVERT System offers physicians the opportunity to lower contrast dye usage which may ultimately protect the kidneys of the many patients who are at risk for CIN”.

Mike McCormick, President and CEO of Osprey Medical, commented: “Successfully driving physician awareness via leading industry peer reviewed scientific publications by key opinion leading physicians such as Dr Kaye and Dr Duffy, is expected to be of great assistance to the commercialisation of AVERT System. We look forward to publication of additional tier one scientific data of the AVERT System in the future.

We are currently underway with a randomized, multi-center, IDE trial of the AVERT System, with first patient enrolment imminent. In addition to evaluating the effectiveness of the AVERT System for CIN reduction, the trial will also measure economics savings with use of the AVERT System.”

Further information:

About the AVERT™ System

The Avert System consists of a re-usable contrast modulator with easy to adjust settings. A disposable modulation reservoir easily loads into the contrast modulator unit and attaches to commonly used manual injection systems used by interventional cardiologists during heart procedures.

About the AVERT Trial

The aim of the trial is to support expansion of the AVERT System’s marketing claim to include “reduction of contrast induced nephropathy (CIN)”. Patients who are at-risk for CIN with pre-existing stage 3-4 chronic kidney disease undergoing a heart procedure such as angioplasty and stenting may be eligible to participate in the trial. The trial will enroll approximately 700 patients at up to 45 sites in the U.S., Europe, Canada, Australia, and New Zealand. The Company is aiming to complete enrollment, submit for and obtain FDA clearance for the expanded claim in the first half of 2015. Further information is available at www.ospreymed.com on the “Clinical” page.

About Osprey Medical

Osprey Medical’s core technologies originated from research conducted by Dr. David Kaye at Melbourne’s Baker IDI Heart and Diabetes Institute. Osprey is focused on improving patients’ quality of life by protecting those with chronic kidney disease from contrast induced nephropathy (CIN) and preventing limb amputation in diabetic patients with advanced foot infections.

The Company’s primary product, the AVERT™ System, is designed to reduce the amount of dye (contrast) injected during commonly performed heart procedures, thus protecting kidneys from damaged known as contrast induced nephropathy (CIN). Osprey Medical’s Limb Recovery™ System is a percutaneous technology that allows physicians to deliver targeted doses of antibiotics to the lower limb in patients with diabetes suffering from advanced foot infections.

Osprey Medical’s Board and Management are comprised of experienced and successful personnel with established track records covering medical device development, regulatory approvals, sales and marketing, and mergers-acquisitions. Osprey Medical’s advisory board comprises world-recognised experts in heart and kidney diseases.

Contact details:
Media
Haley Price
Buchan Consulting
T: (613) 986 64772
M: (61) 423 139 163
Investors
Rebecca Wilson
Buchan Consulting
M: (61) 417 382 391
Company
Doug Schoenberg
VP of Marketing
T: (952) 955 8230

Greensboro, NC November 18, 2013 – In June the US Food and Drug Administration’s Center for Veterinary Medicine approved the first application of Piedmont Pharmaceuticals’ invention of a soft chew formulation containing a veterinary medicine. This flavored soft chew formulation contains carprofen and is labeled for the relief of pain and inflammation from osteoarthritis and the control of post-operative pain in dogs. It is the first and only flavored, soft and chewable medicine in the pain category.

Beyond the Animal Health sector this soft chew formulation is patented for use in delivering human pharmaceutical medications orally. Piedmont has demonstrated positive data supporting the use of two common OTC medications in a berry flavored soft chew. According to Roland Johnson, Chairman and CEO of Piedmont Pharmaceuticals, “We are looking to partner with human Pharmaceutical companies to bring this novel formulation to patients. We believe soft chew medicines will have value as part of a post patent strategy and will improve compliance with the medicating process. As an example, there are consumers who struggle or dislike swallowing pills and for whom a chewable is much more acceptable.” In addition Johnson noted that, “this formulation has been issued multiple US and international patents in the past two years.”

Piedmont Pharmaceuticals is a company that develops innovative FDA and EPA regulated medicines, medical devices and related technologies for animal and human use.

Minnesota, United States and Melbourne, Australia – November 18, 2013 – Osprey Medical Inc. (ASX: OSP) today
announced that Dr. Roxana Mehran will be the Principal Investigator (PI) of the AVERT Trial. This trial will evaluate
the Company’s AVERT™ System for a marketing claim expansion to include “reduction of Contrast Induced
Nephropathy (CIN)” for patients undergoing angiogram or stenting procedures.

The randomized, multi-center, IDE trial will be enrolling approximately 700 patients at up to 45 sites in the U.S.,
Canada, Europe, Australia, and New Zealand. Dr Mehran is a U.S. interventional cardiologist with world-recognized
expertise in the area of CIN. She is Professor of Medicine and Director of Interventional Cardiovascular Research at
Mount Sinai Hospital in New York. Dr. Mehran is internationally renowned for her work as a clinical trial specialist
within the field of interventional cardiology and for her expertise in working with regulatory agencies to conduct
trials.

Dr. Mehran stated: “For years, the cardiology community has been looking for potential solutions to prevent CIN in
those patients at risk for acute kidney injury, and I am excited to be leading the AVERT clinical trial effort to evaluate
this technology.”

Osprey Medical also announced that Dr. Gregg Stone will serve as Chairman of the AVERT Trial’s Steering
Committee, which provides strategic direction and oversight of publications. Dr. Stone is Professor of Medicine and
the Director of Cardiovascular Research and Education at New York-Presbyterian Hospital/Columbia University
Medical Center. He is also the Co-Director of Transcatheter Cardiovascular Therapeutics (TCT), the world’s largest
symposium on interventional cardiology and vascular medicine.

In addition to evaluating the effectiveness of the AVERT System for CIN reduction, the trial will include a health
economics sub-study to evaluate potential benefits for patients, hospitals, and payers. The Primary Investigator for
the health economic sub-study will be Dr. James Tumlin, a practicing nephrologist and Professor of Medicine at the
University of Tennessee in Chattanooga. Dr. Tumlin is widely acknowledged as a thought leader in acute kidney
injury, with over 20 years of clinical research and numerous publications on kidney disease and contrast induced
nephropathy.

Mike McCormick, President and CEO of Osprey Medical, commented: “We are pleased to have a world-recognized
medical team leading our AVERT clinical trial efforts. The AVERT System’s ability to reduce the amount of dye used
in commonly performed heart procedures may provide a significant benefit in patients with at-risk kidneys.” The
trial will commence in Q4 CY 2013. The Company is aiming to complete enrollment, submit for and obtain FDA
clearance for the expanded claim in the first half of 2015.

Further information is available at www.ospreymed.com on the “Clinical” page.

Further information:

About the AVERT™ System

The Avert System consists of a re-usable contrast modulator with easy to adjust settings. A disposable modulation reservoir
easily loads into the contrast modulator unit and attaches to commonly used manual injection systems used by interventional
cardiologists during heart procedures.

About the AVERT Trial

The aim of the trial is to support expansion of the AVERT System’s marketing claim to include “reduction of contrast induced
nephropathy (CIN)”. Patients who are at-risk for CIN with pre-existing stage 3-4 chronic kidney disease undergoing a heart
procedure such as angioplasty and stenting may be eligible to participate in the trial. The trial will enroll approximately 700
patients at up to 45 sites in the U.S., Europe, Canada, Australia, and New Zealand. The trial will commence in Q4 CY 2013. The
Company is aiming to complete enrollment, submit for and obtain FDA clearance for the expanded claim in the first half of 2015.

About Osprey Medical

Osprey Medical’s core technologies originated from research conducted by Dr. David Kaye at Melbourne’s Baker IDI Heart and
Diabetes Institute. Osprey is focused on improving patients’ quality of life by protecting those with chronic kidney disease from
contrast induced nephropathy (CIN) and preventing limb amputation in diabetic patients with advanced foot infections. The
Company’s primary product, the AVERT™ System, is designed to reduce the amount of dye (contrast) injected during commonly
performed heart procedures, thus protecting kidneys from damaged known as contrast induced nephropathy (CIN). Osprey
Medical’s Limb Recovery™ System is a percutaneous technology that allows physicians to deliver targeted doses of antibiotics to
the lower limb in patients with diabetes suffering from advanced foot infections.

Osprey Medical’s Board and Management are comprised of experienced and successful personnel with established track records
covering medical device development, regulatory approvals, sales and marketing, and mergers-acquisitions. Osprey Medical’s
advisory board comprises world-recognised experts in heart and kidney diseases.

Contact details:
Media
Haley Price
Buchan Consulting
T: (613) 986 64772
M: (61) 423 139 163
Investors
Rebecca Wilson
Buchan Consulting
M: (61) 417 382 391
Company
Doug Schoenberg
VP of Marketing
T: (952) 955 8230

EDEN PRAIRIE, Minn., Oct. 29, 2013 (GLOBE NEWSWIRE) — Sunshine Heart, Inc. (Nasdaq:SSH) announced today that the
initial C-Pulse® System patient data of its ongoing OPTIONS HF EU trial, will be presented by Professor Thomas Krabatsch,
Director of Mechanical Circulatory Support at the German Heart Institute, Berlin to the investment community at Sunshine
Heart’s third annual analyst breakfast event, held this morning at 7:30 a.m. PDT at the W Hotel San Francisco. As announced
on October 22, 2013, the event also includes presentations from Dr. Andrew Kao, Associate Professor of Medicine at the
University of Missouri-Kansas City; as well as Dr. William Cohn, Director of Minimally Invasive Surgical Technology of Texas
Heart Institute. Following the event, the presentations and audio will be available on the investor section of the Sunshine Heart
website at: http://ir.sunshineheart.com/index.cfm.

Initiated in February, 2013, the OPTIONS HF study is a post-market, multi-center, prospective, open label study that will include
50 patients in up to ten European centers. The study is designed to observe clinical outcomes of heart failure patients treated
with the C-Pulse system concurrent with the Company’s COUNTER HF™ US pivotal trial. The primary endpoint is identical to
the COUNTER HF trial as it evaluates rate of re-hospitalization due to worsening heart failure and heart failure related death.

On October 28th, Professor Krabatsch, with cooperation from Dr. Holger Hotz at Cardio Centrum Berlin, presented initial
OPTIONS HF study data on patients implanted at the German Heart Center, Berlin at the 2013 TCT conference as part of
Session III: LVAD’s for “Less Sick Patients.” Data presented included 15 cumulative days of C-Pulse therapy across five
individual patients, four of which remain on C-Pulse therapy. An additional two patients have been implanted at other centers
and are not included in this presentation. As presented by Dr. Krabatsch, the four patients on C-Pulse therapy range from 51
to 63 years of age, and include three patients classified as NYHA Class III and one classified as NYHA ambulatory Class IV. All
four patients are currently at home with the device. Early results indicate that surgical implantation without cardiopulmonary
bypass was successful in all patients with no reports of stroke, myocardial infarction, major bleeding or infection (exit site or
otherwise) due to the device. In addition, there have been no re-hospitalizations due to worsening heart failure or heart failure
related death, which is the primary endpoint in the U.S. COUNTER HF trial. High compliance ( > 90%) has been reported thus
far, with patients disconnecting only for battery charge or showering. In addition, patients and physicians report high
satisfaction with the device. Dr. Krabatsch also summarized results from two specific trial patients, presented earlier this year at
ESAIO in Scotland on September 13, 2013. Data included encouraging improvement across both patients within left and right
ventricle ejection fraction, and one patient reported improving from NYHA Class III heart failure at baseline to NYHA Class II
after just six weeks on the device. The same patient reported a 74% increase in observed six minute walk score at six weeks,
improving to 418m from 240m at baseline. Further information will be available during the Company’s third quarter earnings call
on November 11th at 9:00 a.m. EST.

Dr. Kao’s presentation provides data from a single center, St. Luke’s Mid America Heart Institute. The Company had previously
announced that two patients from the U.S. North American Feasibility study had been fully weaned from the device. Dr. Kao’s
presentation profiles three additional patients implanted with the C-Pulse device from the feasibility trial as well. Two of the
patients have now been successfully weaned from the device following significant improvements in both heart failure NYHA
classification, ejection fractions, and heart failure related symptoms; while a third patient is in the process of being weaned.
Patient profiles include C-Pulse usage and key heart failure metrics along the progression of treatment, as well as individual
lessons learned from each patient. The Company will not allow weaning in the U.S. COUNTER HF trial to prevent any impact on
the clinical results.

Dr. William Cohn’s presentation unveils the most recent advancements in the developing C-Pulse fully-implantable system,
including system design, capabilities and upcoming test plans. The device will be non-blood contacting and non-obligatory,
providing the patient with active inflation without the necessity for an implanted battery. In addition, the system will also
eliminate the exit site, as well as percutaneous lead and associated infection risks.

Sunshine Heart will release its third quarter operating results and clinical trial update before the market open on November 11,
2013. Subsequent to the quarterly release, the Company will host a conference call at 9:00 a.m. EST.

About the C-Pulse® Heart Assist System

The C-Pulse Heart Assist System, or C-Pulse System, an investigational device in the United States, Canada and countries that
do not recognize the CE mark approval, utilizes the scientific principles of intra-aortic balloon counterpulsation applied in an
extra-aortic approach to assist the left ventricle by reducing the workload required to pump blood throughout the body, while
increasing blood flow to the coronary arteries. Combined, these potential benefits may help sustain the patient’s current
condition or, in some cases, reverse the heart failure process, thereby potentially preventing the need for later-stage heart
failure devices, such as left ventricular assist devices (LVADs), artificial hearts or transplants. It may also provide relief from the
symptoms of Class III and ambulatory Class IV heart failure and improve quality of life and cardiac function. Based on the
results from our feasibility trial, we also believe that some patients treated with our C-Pulse System will be able to stop using the
device due to sustained improvement in their condition as a result of the therapy.

Caution: Investigational device, limited by Federal (or United States) Law to Investigational use.

About Sunshine® Heart

Sunshine Heart, Inc. is a medical device company focused on developing, manufacturing and commercializing the C-Pulse
System for treatment of Class III and ambulatory Class IV heart failure. Sunshine Heart has completed an approved U.S. Food
and Drug Administration (FDA) feasibility clinical trial of the C-Pulse System and presented the results in November 2011. In
March 2012, the FDA notified the Company that it could move forward with an investigational device exemption (IDE)
application. Sunshine Heart received unconditional approval from the FDA in November 2012 to initiate its pivotal trial. In
July 2012 Sunshine Heart received CE Mark approval for its C-Pulse System in Europe. Sunshine Heart is a Delaware
corporation headquartered in Minneapolis with a wholly owned subsidiary in Australia. The Company has been listed on the
NASDAQ Capital Market since February 2012.

Forward-Looking Statements

Certain statements in this release are forward-looking statements that are based on management’s beliefs, assumptions,
expectations, and information currently available to management. All statements that address future operating performance,
events or developments that we expect or anticipate will occur in the future are forward-looking statements, including, without
limitation, future clinical trial activities and results including patient enrollment in trials. These forward-looking statements are
subject to numerous risks and uncertainties, including, without limitation, the possibility that our clinical trials do not meet their
enrollment goals, meet their endpoints or otherwise fail, that regulatory authorities do not accept our application or approve the
marketing of the C-Pulse System, the possibility that we may be unable to raise the funds necessary for the development and
commercialization of our products, that we may not be able to commercialize our products successfully in the European Union
and the other risk factors described under the caption “Risk Factors” and elsewhere in our filings with the Securities and
Exchange Commission. You should not place undue reliance on forward-looking statements because they speak only as of the
date when made and may turn out to be inaccurate. We do not assume any obligation to publicly update or revise any forwardlooking
statements, whether as a result of new information, future events or otherwise. We may not actually achieve the plans,
projections or expectations disclosed in forward-looking statements, and actual results, developments or events could differ
materially from those disclosed in the forward-looking statements.

CONTACT:
Media:
Laura Forman
Blueprint Life Science Group
T: +1-415-375-3340
Investor:
Jeff Mathiesen
Chief Financial Officer
Sunshine Heart, Inc.
T: +1-952-345-4200

Minnesota, United States and Melbourne, Australia – October 22, 2013 – Osprey Medical Inc. (ASX:
OSP) today announced the first patient enrolment in its Limb Recovery™ System efficacy study. This
technology allows clinicians to use existing antibiotic therapy in a more targeted and aggressive way in
patients with diabetes who present with life or limb threatening foot infections. The patient was
enroled at the Royal Melbourne Hospital in Melbourne, Australia.

Osprey’s efficacy study will involve a 20 patient randomized clinical trial comparing the effectiveness of
Osprey’s percutaneous perfusion Limb Recovery System with standard intravenous delivery of antibiotic
therapy for treatment of severe limb infections. The system enables the circulation of the limb to be
isolated and separated from the general circulatory system, permitting the delivery of antibiotic drugs at
higher and sustained doses that are otherwise unachievable with standard intravenous care. This is
achieved by creating an “artificial” circuit by inserting catheters into the major artery and vein of the
lower limb.

In July 2013, the Company announced completion of a five patient pilot safety study for the technology.
The primary investigator, Associate Professor Paul Wraight, said: “After successfully completing the pilot
safety study, we are excited to begin the efficacy study which will help us to determine how effective
this technology is at managing high risk foot infections in patients with diabetes. The potential to offer a
treatment option for patients who are at significant risk of requiring major limb amputation may benefit
people that have no alternatives.”

It is estimated that more than 360 million people worldwide have diabetes, a number expected to
increase by more than 50% by 2030.i People with diabetes are particularly prone to diabetic limb and
foot infections due to insufficient blood flow and impaired wound healing. Standard oral or intravenous
delivery of antibiotics is often ineffective in these patients because dosage levels cannot be achieved at
a sufficient level at the site of the limb infection. Infections of the lower limb are the leading cause of
amputations globally, leading to increased rates of hospitalisation and higher healthcare costs
throughout the developed world.

About Diabetic Limb Infections

Diabetes is a growing national epidemic in many developed countries. Research shows that approximately 8% of
the US and Australian populations have diabetes.^ii,iii Diabetes related foot pathology is the most frequent cause of
hospitalisations, with at least 15% of all hospital admissions ^iv and includes conditions such as foot ulcers, infections,
and gangrene. The combination of difficult to treat infection with poor wound healing and poor blood supply can
lead to significant patient complications including lower limb amputations. It is estimated that there are more
than 100,000 lower limb amputations annually in the US and Australia.^v,vi

About the Victorian Government’s Market Validation Program (Australia)

Osprey Medical’s clinical study for its Limb Recovery System, conducted at the Royal Melbourne Hospital, has
received funding through the Victorian Government’s Market Validation Program, which seeks to engage with
both government and business to promote innovation.

About the Royal Melbourne Hospital

The Royal Melbourne Hospital is one of Australia’s pre-eminent hospitals. It provides world-leading clinical care,
extensive surgical and medical expertise and outstanding research, built on its foundation as a university teaching
hospital. The Royal Melbourne Hospital provides the full range of tertiary/quaternary level medical and surgical
services including cardiac, neuroscience, oncology and trauma services as well as sub-acute care, aged care,
rehabilitation, ambulatory care, and residential and community services. The Royal Melbourne Hospital is a
privileged member of Melbourne’s world-leading Parkville Precinct, and enjoys strong relationships with many of
the city’s major universities and research institutes. Through these partnerships, The Royal Melbourne Hospital is
committed to improving patient care through translating research outcomes into clinical practice.

About Osprey Medical

Osprey Medical’s core technologies originated from research conducted by Dr David Kaye at Melbourne’s Baker IDI
Heart and Diabetes Institute. Osprey is focused on improving patients’ quality of life by protecting those with
chronic kidney disease from contrast induced nephropathy (CIN) and preventing limb amputation in diabetic
patients with advanced foot infections. The Company’s primary product, the AVERT™ System, is designed to
reduce the amount of dye (contrast) injected during commonly performed heart procedures, thus protecting
kidneys from damaged known as contrast induced nephropathy (CIN). Osprey Medical’s Limb Recovery™ System is
a percutaneous technology that allows physicians to deliver targeted doses of antibiotics to the lower limb in
patients with diabetes suffering from advanced foot infections.

Osprey Medical’s Board and Management are comprised of experienced and successful personnel with established
track records covering medical device development, regulatory approvals, sales and marketing, and mergersacquisitions.
Osprey Medical’s advisory board comprises world-recognised experts in heart and kidney diseases.

For further information, please contact:

Haley Price
Buchan Consulting
T: (613) 9866 4722
M: (613) 423 139 163

Doug Schoenberg
VP of Marketing, Education & Reimbursement
T: (952) 955 8234
M: (763) 258 7537

ⁱInternational Working Group on the Diabetic Foot. (www.iwgdf.org)
ⁱⁱCenters for Disease Control and Prevention. National diabetes fact sheet: national estimates and general information on diabetes and prediabetes in the United
States, 2011. Centers for Disease Control and Prevention.
ⁱⁱⁱDunstan DW, et al. The rising prevalence of diabetes and impaired glucose tolerance: The Australian Diabetes, Obesity and Lifestyle Study. Diabetes Care. 2002
May;25(5):829-34.
^ivHill SL, et al. The effects of peripheral vascular disease with osteomyelitis in diabetic foot. American Journal of Surgery. 1999. 177:282-6.
^vMichael J McCarthy, Lower-Leg Amputations are Increasing. Wall Street Journal

Brings enterprise-grade endpoint data protection to public sync and share services

SEATTLE, October 1st, 2013 – Datacastle®, a market leader for protecting enterprises from endpoint data loss and data breaches, today announced that its flagship product, Datacastle RED™  now supports secure backup and restore of company data when using major cloud sync and share services such as DropBox, Microsoft SkyDrive, Box, Google Drive, and Amazon Cloud Drive. This new capability is added to Datacastle’s recognized QuickCache™ and RoamSmart™ technologies that support intelligent backup and recovery roaming across hybrid cloud deployments with mobile broadband detection functionality.

“While many vendors in the enterprise IT sector are trying to provide companies with a “rip and replace” alternative to these wildly popular cloud sync and share services, we believe CIO’s should have an “embrace and extend” option,” says Datacastle CEO Ron Faith. “With our latest release of Datacastle RED, CIO’s can augment their data governance and compliance when employees use these services.”

In addition to enabling IT professionals to backup and restore company data stored in employee public sync and share accounts, Datacastle RED makes it possible to encrypt the sync and share data “at rest” on laptops, desktops, or high-end Windows tablets such as the Surface Pro. IT administrators can also remotely wipe the data at the endpoint by command or poison pill.

The most recent release also enhances Datacastle RED’s enterprise capabilities concerning automated silent deployment, Active Directory/LDAP integration, single sign-on support via SAML v2, and centralized policy management.

Datacastle RED is available on Microsoft Windows Azure, IBM SmartCloud, and on-premise deployments.

About Datacastle

Datacastle protects enterprises from mobile data loss and data breach with simplified and scalable endpoint backup and data protection. Datacastle RED provides secure and auditable access to enterprise data on critical devices, anytime, anywhere. Datacastle RED is available through a global network of partners. To learn more about Datacastle RED, visit http://www.datacastlered.com, follow on Twitter @Datacastle, or call 425.996.9684.

Media Contacts

– See more at: http://www.datacastlecorp.com/site/press-releases/datacastle-announces-support-for-cloud-sync-and-share-services.html#sthash.KS4c2FuB.dpuf

EDEN PRAIRIE, Minn., Sept. 24, 2013 (GLOBE NEWSWIRE) — Sunshine Heart, Inc. (Nasdaq:SSH) announced today the
closing of its previously announced underwritten public offering of 4,381,500 shares of its common stock, which includes the full
overallotment of 571,500 shares, at a price to the public of $10.50 per share. The net proceeds from the sale of shares by
Sunshine Heart, after underwriting discounts and other offering expenses, total approximately $42.6 million.

Piper Jaffray & Co. and Cowen and Company, LLC acted as joint book-running managers and Lazard Capital Markets LLC
acted as co-lead manager for the offering. Craig-Hallum Capital Group and Northland Securities, Inc. acted as co-managers for
the offering.

Sunshine Heart currently intends to use the net proceeds from the offering for general corporate purposes, including its
ongoing U.S. pivotal trial and post-market EU study, initial commercialization of the C-Pulse® Heart Assist System, or C-Pulse
System, in the EU, and product development activities.

The offering was made pursuant to a shelf registration statement (File No. 333-187273) (including a prospectus) previously
filed with and declared effective by the SEC. Prospective investors should read the prospectus in that registration statement,
the final prospectus relating to the offering, and other documents that Sunshine Heart has filed with the SEC for more complete
information about Sunshine Heart and the offering. A copy of the prospectus supplement and the accompanying prospectus
relating to these securities may be obtained by contacting Piper Jaffray & Co., Attention: Prospectus Department, 800 Nicollet
Mall, Suite 1000, Minneapolis, MN 55402, or by telephone at (800) 747-3924, or by e-mail at prospectus@pjc.com, or by
contacting Cowen and Company, LLC (c/o Broadridge Financial Services, 1155 Long Island Avenue, Edgewood, NY, 11717,
Attn: Prospectus Department, Phone: 631-274-2806, Fax: 631-254-7140). Electronic copies of the prospectus supplement and
the accompanying prospectus are also available free of charge on the website of the SEC at www.sec.gov.

This press release does not constitute an offer to sell or a solicitation of an offer to buy any securities, nor shall there be any
sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or
qualification under the securities laws of any such jurisdiction.

About Sunshine® Heart

Sunshine Heart, Inc. (Nasdaq:SSH) is a medical device company focused on developing, manufacturing and commercializing
the C-Pulse System for treatment of Class III and ambulatory Class IV heart failure. Sunshine Heart has completed an
approved U.S. Food and Drug Administration (FDA) feasibility clinical trial of the C-Pulse System and presented the results in
November 2011. In March 2012, the FDA notified the Company that it could move forward with an investigational device
exemption (IDE) application. Sunshine Heart received unconditional approval from the FDA in November 2012 to initiate its
pivotal trial. In July 2012 Sunshine Heart received CE Mark approval for its C-Pulse System in Europe. Sunshine Heart is a
Delaware corporation headquartered in Minneapolis with a wholly owned subsidiary in Australia. The Company has been listed
on the NASDAQ Capital Market since February 2012.

Forward-Looking Statements

Certain statements in this release are forward-looking statements that are based on management’s beliefs, assumptions and
expectations and information currently available to management. All statements that address future operating performance,
events or developments that we expect or anticipate will occur in the future are forward-looking statements, including, without
limitation, our expectations with respect to the net proceeds from the offering and the ultimate uses thereof, future clinical trial
activities and results including patient enrollment in trials. These forward-looking statements are subject to numerous risks and
uncertainties, including, without limitation, the possibility that our clinical trials do not meet their enrollment goals, meet their
end-points or otherwise fail, that regulatory authorities do not accept our application or approve the marketing of the C-Pulse
System, the possibility that we may be unable to raise the funds necessary for the development and commercialization of our
products, that we may not be able to commercialize our products successfully in the EU and the other risk factors described
under the caption “Risk Factors” and elsewhere in our filings with the SEC. You should not place undue reliance on forwardlooking
statements because they speak only as of the date when made and may turn out to be inaccurate. We do not assume
any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future
events or otherwise. We may not actually achieve the plans, projections or expectations disclosed in forward-looking
statements, and actual results, developments or events could differ materially from those disclosed in the forward-looking
statements.

CONTACT: For further information, please contact:
Media:
Laura Forman
Blueprint Life Science Group
T: +1-415-375-3340
Investor:
Jeff Mathiesen
Chief Financial Officer
Sunshine Heart, Inc.
T: +1-952-345-4200

Mesaplexx has been shortlisted as a potential ‘Innovator of the Year’ in the Growing Business Awards, the most widely supported national awards program, recognising successful UK SMEs and entrepreneurs. Backed by Lloyds Bank, The CBI and RealBusiness Magazine, the awards have celebrated successful British businesses for the past 15 years.

Mesaplexx’s xCube technology has also been nominated to receive a Global Business Excellence Award for Outstanding Innovation, an awards program that recognises and rewards business excellence in all sectors.

The patented xCube range of filters and duplexers for carrier grade small cells and active antennas from Mesaplexx offer mobile network vendors high power handling, low insertion loss and high isolation in a light, compact, cool-running format.

Peter Young, VP Commercial, Mesaplexx said: “Industry feedback has already proven that Mesaplexx and our revolutionary xCube technology have the potential to be a game-changer in the LTE market. Being shortlisted for these awards is testament to our development team and our innovative, breakthrough approach to solving the problem of how to deliver high performance filter technology in a small, compact form factor.”

About Mesaplexx:
 Mesaplexx develops and licenses compact, high performance filter technology for the mobile industry. These filters enable better small cell, active antenna and compact radio systems, leading to better mobile networks.
 Our xCube™ filter technology is sold under license to telecoms vendors who are actively seeking new ways of helping mobile operators to rapidly develop next generation technologies to deliver increased network capacity.

For more information, please contact:

Jo Ben Rais, Head of Marketing, 
Mesaplexx.
+44 (0) 1273 960288   |   
 jo.benrais@mesaplexx.com

EDEN PRAIRIE, Minn., Sept. 12, 2013 (GLOBE NEWSWIRE) — Sunshine Heart, Inc. (Nasdaq:SSH) announced today the first
patient implant in the Company’s U.S. pivotal trial, COUNTER HF. The COUNTER HF study is a prospective, randomized, multicenter,
controlled trial that will evaluate the safety and efficacy of the C-Pulse system for the treatment of NYHA Class III and
ambulatory Class IV heart failure. Integral to the COUNTER HF study is the assessment of C-Pulse’s unique balloon
counterpulsation treatment designed to improve heart function and reduce re-hospitalizations due to worsening heart failure.

“We are excited to be part of this innovative clinical trial,” said cardiothoracic surgeon, Sanjeev Aggarwal, M.D., Director of
Mechanical Circulatory Support and principal study investigator at Saint Luke’s Mid America Heart Institute of Kansas City.
“Based on the positive clinical results from our experience during the feasibility study, we are very much looking forward to
participating in the COUNTER HF pivotal study. The C-Pulse system, in comparison to other devices used for circulatory
support, offers the advantage of implantation through a truly minimally invasive approach without the need for cardiopulmonary
bypass or sternal division. Its non-blood contacting interface obviates the need for anticoagulation and allows patients to
untether from the device for short periods of time. We are excited to have the opportunity to further investigate the potential
benefits of this technology in heart failure patients through this important pivotal study.”

“The COUNTER HF study is important for the many heart failure patients who are not being successfully treated with existing
therapies,” said David Rosa, CEO of Sunshine Heart. “We are pleased to have St. Luke’s Mid-America Heart Institute enroll and
implant our first patient in the COUNTER HF pivotal trial. They were the top enrolling clinical site in our recently completed U.S.
FDA C-Pulse system feasibility study and we look forward to their continued leadership in this trial.”

About the COUNTER HF Study

The COUNTER HF study is a prospective, randomized, multi-center clinical trial. It is being conducted by heart failure and
cardiac surgeon specialists in the United States. It is expected to enroll 388 patients in up to 40 clinical sites. The purpose of
the study is to determine whether the C-Pulse System is a safe and effective treatment for heart failure patients who meet the
following key study qualifications:

• NYHA Class III or early Class IV heart failure*;
• Ejection fraction ≤ 35% (measure of how well the heart pumps blood);
• Taking appropriate heart failure medications as prescribed by doctor; and
• Have been evaluated for cardiac resynchronization therapy with or without defibrillation (CRT, CRT-D) or implantable
• cardioverter defibrillator (ICD) therapy.

*New York Heart Class (NYHA) Class III or early Class IV: Very limited in daily activities or unable to do activities without
discomfort. Become tired, short of breath, and have heart palpitations during physical activity. Note: Other qualifications apply
and study doctors will determine who is eligible for the study.

Individuals who are interested in learning more about the trial and if they might qualify for the study can visit
www.HFClinicalStudy.com or call 1-888-978-8391.

About Congestive Heart Failure

Heart failure affects over 5 million Americans and is responsible for more than 1 million hospitalizations in the United States
each year.^1,2 It is a costly disease, with an estimated $32 billion total costs associated with it in the United States.1 Patients with
heart failure have a poor quality of life and reduced life expectancy, with 50% dying within 5 years.3,4 There are few effective
treatments for patients with advanced heart failure. It is estimated that 1.2 American suffer from moderate heart failure (NYHA
Class III).^1.5

About C-Pulse System

The C-Pulse system is an investigational treatment and is a unique approach for treating moderate to severe heart failure. It
uses proven balloon counterpulsation technology to assist the heart by reducing the workload of the left ventricle, while
increasing blood flow to the heart muscle. The C-Pulse system does not replace the heart function, but rather is designed to
assist the heart in doing its job. The System includes the following key components: Cuff, Sensing Lead, Interface Lead and
Driver.

The C-Pulse Cuff wraps around the outside of the ascending aorta (the main artery coming out of the heart that delivers blood
to the body), much like a blood pressure cuff around your arm. It is connected to the Driver (the pump) by a tube (Interface
Lead) that passes through a small hole in the skin. The C-Pulse Cuff pumps in rhythm with the natural heartbeat, which is
monitored using a pacemaker-type wire, called a Sensing Lead. The Cuff deflates just before the heart pumps blood, reducing
the workload of the heart. The Cuff is timed to re-inflate in between heartbeats, once the heart has finished pumping blood –
this allows the Cuff to act like a second heartbeat, producing a surge of blood flow to the heart muscle. The Driver includes a
small rechargeable battery, which provides the power for the C-Pulse System.

The C-Pulse is designed to treat heart failure and reduce heart failure symptoms by:

•  Reducing the workload of the heart;
•  Providing more oxygen-rich blood going to the heart muscle; and
•  Improving heart function.

Combined, these potential benefits may reverse the heart failure process, thereby potentially preventing the need for laterstage
heart failure devices, such as left ventricular assist devices (LVADs), artificial hearts or transplants. There is a potential
additional long-term benefit of having patients discontinue use of the device due to sustained improvement in their condition as
a result of the therapy. This occurred in some feasibility study patients.

The C-Pulse system is implanted without any incisions into the heart itself or to any major vessels. It does not come in contact
with the internal blood system. Patients can disconnect with it for short periods of time if needed. It may be used in combination
with other approved devices and medications for treating heart failure.

About Sunshine® Heart
Sunshine Heart, Inc. (Nasdaq:SSH) is a medical device company focused on developing, manufacturing and commercializing
the C-Pulse system for treatment of Class III and ambulatory Class IV heart failure. Sunshine Heart has completed an approved
U.S. Food and Drug Administration (FDA) feasibility clinical trial of the C-Pulse system and presented the results in
November 2011. In March 2012, the FDA notified the Company that it could move forward with an investigational device
exemption (IDE) application. Sunshine Heart received unconditional approval from the FDA in November 2012 to initiate its
pivotal trial. In July 2012 Sunshine Heart received CE Mark approval for its C-Pulse system in Europe. Sunshine Heart is a
Delaware corporation headquartered in Minneapolis with a wholly owned subsidiary in Australia. The Company has been listed
on the NASDAQ Capital Market since February 2012.

Forward-Looking Statements
Certain statements in this release are forward-looking statements that are based on management’s beliefs, assumptions,
expectations, and information currently available to management. All statements that address future operating performance,
events or developments that we expect or anticipate will occur in the future are forward-looking statements, including, without
limitation, future clinical trial activities and results including patient enrollment in trials. These forward-looking statements are
subject to numerous risks and uncertainties, including, without limitation, the possibility that our clinical trials do not meet their
enrollment goals, meet their endpoints or otherwise fail, that regulatory authorities do not accept our application or approve the
marketing of the C-Pulse System, the possibility that we may be unable to raise the funds necessary for the development and
commercialization of our products, that we may not be able to commercialize our products successfully in the EU and the other
risk factors described under the caption “Risk Factors” and elsewhere in our filings with the SEC. You should not place undue
reliance on forward-looking statements because they speak only as of the date when made and may turn out to be inaccurate.
We do not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new
information, future events or otherwise. We may not actually achieve the plans, projections or expectations disclosed in
forward-looking statements, and actual results, developments or events could differ materially from those disclosed in the
forward-looking statements.

References
1. Heart Disease and Stroke Statistics. American Heart Association—2013 Update. Circulation. 2013;127: e6-e245.
2. Blecker S, et al. J Am Coll Cardiol. 2013;61(12):1259-1267.
3. Levy D, et al. N Engl J Med. 2002;347:1397—1402.
4. Roger VL, et. al. JAMA. 2004;292:344—350.
5. Farwell D, et al. Eur Heart J. 2000;1246-1250.

CAUTION: C-Pulse is an investigational device. The device is limited by Federal (or United States) Law to investigational use
only. It is not available for sale in the United States

C-Pulse is a registered trademark of Sunshine Heart, Inc.
© 2013 Sunshine Heart, Inc. All rights reserved.

CONTACT: For further information, please contact:
Media:
Laura Forman
Blueprint Life Science Group
T: +1-415-375-3340
Investor:
Jeff Mathiesen
Chief Financial Officer
Sunshine Heart, Inc.
T: +1-952-345-4200

Eden Prairie, MN: August 27, 2013: Sunshine Heart, Inc. (NASDAQ: SSH) announced that, effective
today, Patrick Verta, MD, has joined the Company as Chief Medical Officer. Dr. Verta brings
over 20 years of experience in the medical field with the majority of time spent in the
cardiovascular field.

Prior to joining Sunshine Heart, Dr. Verta served as Chief Medical Officer and Vice President of
Clinical Affairs at Neomend, a medical device company that developed and commercialized the
only FDA-approved sealant for air leaks following lung surgery via open thoracotomy. The
company was acquired by Bard/Davol in October 2012. Before Neomend, he served as Medical
Director of Clinical Research and Business Development at Abbott Vascular, where he played a
critical role in the approval of several stent systems used in peripheral vascular disease, in
particular carotid artery stenosis, renal artery stenosis, and peripheral Artery Disease
(PAD). While at Abbott, Dr. Verta led the Carotid Revascularization Endarterectomy versus
Stenting Trial (CREST) PMA, the largest randomized carotid trial ever, enrolling over 2,500
patients and considered today to be the gold standard for carotid stenting trials. Prior to Abbott,
Dr. Verta held the position of Endovascular Clinical Science and Biometrics Director at Guidant
Corporation.

In addition to his experience driving clinical trials, he has co-authored seventeen manuscripts on
novel medical device therapies in peer-review journals, and is credited with two patents in the
data management and electronic data capture areas. Dr. Verta holds a Doctorate of Medicine
from the Faculté de Médecine in Paris, France; as well as a Doctorate of Veterinary Medicine
from the Ecole Nationale Vétérinaire d’Alfort, France. He also completed a Masters Degree in
Biostatistics at the University of Paris.

“We are pleased and fortunate to welcome Dr. Verta to Sunshine Heart as Chief Medical
Officer,” said Dave Rosa, Sunshine Heart’s CEO. “His experience conducting large, complex
clinical trials will be essential as we continue to progress within both our U.S. pivotal trial,
COUNTER HF; as well as our European post-market study, OPTIONS HF. In particular, we look
forward to his contributions toward accelerating and managing prudent site selection and
enrollment with regard to both clinical trials going forward.”

About the C-Pulse® Heart Assist System

The C-Pulse Heart Assist System, or C-Pulse System, an investigational device in the United States,
Canada and countries that do not recognize the CE mark approval, utilizes the scientific principles of
intra-aortic balloon counterpulsation applied in an extra-aortic approach to assist the left ventricle by
reducing the workload required to pump blood throughout the body, while increasing blood flow to the
coronary arteries. Combined, these potential benefits may help sustain the patient’s current condition or,
in some cases, reverse the heart failure process, thereby potentially preventing the need for later-stage
heart failure devices, such as left ventricular assist devices (LVADs), artificial hearts or transplants. It may
also provide relief from the symptoms of Class III and ambulatory Class IV heart failure and improve
quality of life and cardiac function. Based on the results from our feasibility trial, we also believe that
some patients treated with our C-Pulse System will be able to stop using the device due to sustained
improvement in their condition as a result of the therapy.

Caution: Investigational device, limited by Federal (or United States) Law to Investigational use.

About Sunshine® Heart

Sunshine Heart, Inc. (NASDAQ: SSH) is a medical device company focused on developing,
manufacturing and commercializing the C-Pulse System for treatment of Class III and ambulatory Class
IV heart failure. Sunshine Heart has completed an approved U.S. Food and Drug Administration (FDA)
feasibility clinical trial of the C-Pulse System and presented the results in November 2011. In March
2012, the FDA notified the Company that it could move forward with an investigational device exemption
(IDE) application. Sunshine Heart received unconditional approval from the FDA in November 2012 to
initiate its pivotal trial. In July 2012 Sunshine Heart received CE Mark approval for its C-Pulse System
in Europe. Sunshine Heart is a Delaware corporation headquartered in Minneapolis with a wholly owned
subsidiary in Australia. The Company has been listed on the NASDAQ Capital Market since
February 2012.

Forward-Looking Statements

Certain statements in this release are forward-looking statements that are based on management’s beliefs,
assumptions, expectations, and information currently available to management. All statements that
address future operating performance, events or developments that we expect or anticipate will occur in
the future are forward-looking statements, including, without limitation, future clinical trial activities and
results including patient enrollment in trials. These forward-looking statements are subject to numerous
risks and uncertainties, including, without limitation, the possibility that our clinical trials do not meet
their enrollment goals, meet their endpoints or otherwise fail, that regulatory authorities do not accept our
application or approve the marketing of the C-Pulse System, the possibility that we may be unable to raise
the funds necessary for the development and commercialization of our products, that we may not be able
to commercialize our products successfully in the EU and the other risk factors described under the
caption “Risk Factors” and elsewhere in our filings with the SEC. You should not place undue reliance
on forward-looking statements because they speak only as of the date when made and may turn out to be
inaccurate. We do not assume any obligation to publicly update or revise any forward-looking statements,
whether as a result of new information, future events or otherwise. We may not actually achieve the plans,
projections or expectations disclosed in forward-looking statements, and actual results, developments or
events could differ materially from those disclosed in the forward-looking statements.

For further information, please contact:

Media:                                                                                                  
Laura Forman                                                                                  
Blueprint Life Science Group                                                    
T: +1-415-375-3340
Investor:
Jeff Mathiesen
Chief Financial Officer
Sunshine Heart, Inc.                                                                   
T: +1-952-345-4200

Datacastle brings enterprise-grade endpoint data protection to the IBM SmartCloud

SEATTLE, June 25th, 2013 – Datacastle®, a market leader for protecting enterprises from endpoint data loss and data breaches, today announced that its flagship product, Datacastle RED is now certified for the IBM SmartCloud and available worldwide through the IBM Partner Network.

Through the partnership both IBM and Datacastle customers will be able to adopt a robust cloud architecture and service model without having to make traditional investments in enterprise IT to support endpoint backup and security. Customers will benefit from IBM’s geographic footprint and security investments as well as the company’s experience as a global service provider.

“Endpoint backup and recovery have become increasingly important as the global workforce has become more mobile and creates more business content on their various endpoint devices, including mobile devices,” says Gartner analysts Pushan Rinnen and Sheila Childs. “If employees don’t back up their endpoint devices regularly, companies may face significant risk if important or sensitive data is lost, stolen or leaked, including R&D setbacks, fines, legal actions and the inability to produce user data in a lawsuit.”

Customers will be able to install a Datacastle RED Vault on the IBM SmartCloud to which data from PCs, laptops and Windows 8 tablets can be encrypted, backed up and protected. If an endpoint device is lost or stolen, data can easily be restored from the central Vault running on the IBM SmartCloud to any smartphone, tablet, or PC.

“Cloud-integrated backup and data protection requires enterprise-class cloud infrastructure for reliability, security, and scalability. Our partnership with IBM enables Datacastle to further help companies leverage existing commitments and investments in IBM products and global services, and more efficiently take endpoint data protection to the cloud with SmartCloud,” says Datacastle CEO Ron Faith.

Datacastle is participating in the World Cloud Forum in London June 26^th and 27^th. See Datacastle RED running on the IBM SmartCloud in Booth 6150.

About Datacastle

Datacastle protects enterprises from mobile data loss and data breach with simplified and scalable endpoint backup and data protection. Datacastle RED provides secure and auditable access to enterprise data on critical devices, anytime, anywhere. Profiled in Gartner’s Hype Cycle for Storage Technologies, 2012, published July 5, 2012, Pushan Rinnen, Dave Russell et al. Datacastle RED is available through a global network of partners. To learn more about Datacastle RED, visit http://www.datacastlered.com, follow on Twitter @Datacastle, or call 425.996.9684.

Media Contacts

– See more at: http://www.datacastlecorp.com/site/press-releases/06252013—datacastle-red-now-available-on-ibm-smartcloud.html#sthash.h5xPDdyD.dpuf

Greensboro, NC.

Last week the US Food and Drug Administration’s Center for Veterinary Medicine approved the first application of Piedmont Pharmaceuticals’ invention of a canine soft chew formulation containing a veterinary medicine. This flavored soft chew formulation contains carprofen and is labelled for the relief of pain and inflammation from osteoarthritis and the control of post-operative pain in dogs. It is the first and only flavored, soft and chewable medicine in the pain category.

The soft chew formulation will provide pet owners with a convenient and friendly way to medicate dogs. According to Roland Johnson, Chairman and CEO of Piedmont Pharmaceuticals, “The veterinary pharmaceutical industry has been working on a soft chew formulation for the past two decades and we are proud, following a relatively short development timeline, to have successfully registered this highly palatable, wonderfully textured product to positively impact the medicating experience for both dogs and their owners.” In addition Johnson noted that, “this formulation has been issued multiple US patents in the past two years.”

Osteoarthritis is a problem for dogs as they get older, particularly for larger breeds. A common sign that owners will notice in their dog is difficulty climbing stairs or jumping into the back of a car. Pain is the third largest veterinary treatment category in companion animal health.

Piedmont Pharmaceuticals is a company that develops FDA and EPA regulated products for animals, emphasizing dogs and cats. In addition, their pipeline includes livestock products along with a group of technology-related human products.

Mesaplexx’s patented xCube filter technology uses multimode resonators with optimized performance-enhancing coupling techniques, to deliver performance characteristics associated with far bigger and heavier duplexers. This makes them ideal for carrier-grade small cell deployments and active antennas, which demand high performance in a small, compact and lightweight package.

The xCube 1800 MHz duplexer features very low insertion loss of 1 dB – 2 dB, with isolation in excess of 85 dB. By reducing insertion loss and increasing isolation, capacity and coverage gains of up to 30% can be realised.

xCube technology also reduces unwanted heat in compact radio systems by up to 50%. This, coupled with xCube’s high sensitivity and low insertion loss, ensures base station capacity  increases of up to 30% can be achieved.

One of the benefits of the 1800 MHz xCube duplexer is that it can be tailored to meet specific vendor designs and requirements.  Peter Young, VP Commercial, Mesaplexx said: “We have already supplied reference designs for our 1800 MHz xCube to several major network equipment vendors. The revolutionary, patented xCube technology, combined with our reference design licensing approach, means that our filters and duplexers can be tailored to individual equipment vendor requirements.

In order to meet their specific needs, we can customize xCube for each frequency band, and even for individual vendor products within any given band. We look forward to announcing availability of the xCube for other frequency bands in the very near future.”

About Mesaplexx:

Mesaplexx develops and licenses compact, high performance filter technology for the mobile industry. These filters enable better compact base station radios, active antenna and carrier grade small cell deployments, leading to better mobile networks.
Our xCube™ filter technology is sold under license to telecoms vendors who are actively seeking new ways of helping mobile operators to rapidly develop next generation technologies to deliver increased network capacity.
Since 2007, Mesaplexx, backed by CM Capital and Southern Cross Venture Partners, has been developing products and intellectual property in electromagnetic engineering, ceramic materials, substrate technologies, EM mathematical modelling and RF filters.

For more information, please contact:

Jo Ben Rais,
Head of Marketing,
Mesaplexx.
+44 (0) 1273 960288
jo.benrais@mesaplexx.com

Datacastle introduces groundbreaking RoamSmart™ technology for protecting mobile workforce data worldwide.

SEATTLE, March 27, 2013 – Datacastle®, a market leader for protecting enterprises from endpoint data loss and data breaches, today announced the release of the latest version of its flagship product, Datacastle RED. Datacastle RED v6 introduces RoamSmart^™ technology for providing network-optimized data protection for increasingly distributed and mobile workforces.

Datacastle’s RoamSmart^™ technology enables IT managers to provide a friction-free end user experience while meeting organizational security and compliance requirements worldwide.

Datacastle’s RoamSmart^™ technology includes:

• LTE, 4G, and 3G mobile broadband detection and backup policy enforcement
• Intelligent roaming between cloud-based vaults and QuickCaches located on corporate LAN’s or remote offices accelerating time to protection and recovery
• Easy and secure mobile data access and sharing from iOS, Android, Windows Phone and Windows RT devices

“With enterprises adopting Windows 8 ultrabooks and tablets, Datacastle RED v6 is the ideal data protection solution for these new powerful mobile computing devices,” said Ron Faith, Datacastle CEO. “Enterprise IT professionals need a solution that is easy to deploy, administer and integrate with their existing Active Directory or LDAP infrastructure.”

Datacastle RED v6 has also been localized to support companies with employees in Asia-Pacific and Latin American regions. Datacastle RED v6 is now available in 10 languages worldwide including Chinese, Japanese, Korean, and Brazilian Portuguese.

Datacastle RED v6 has also been optimized to run on Microsoft’s Windows Azure. “We are very excited that an enterprise-class endpoint data protection solution such as Datacastle RED is being hosted and operated in our world-class Windows Azure cloud,” said Scott Woodgate, Senior Director of Partner and Channel Marketing for Windows Azure.

Datacastle RED v6 is available for on-premise, private cloud, or public cloud deployments directly from Datacastle or from one of Datacastle’s global network of partners. For more information call 425.996.9684 or email sales@datacastlered.com.

About Datacastle

Datacastle protects enterprises from mobile data loss and data breach with simplified and scalable endpoint backup and data protection. The company’s Datacastle RED product provides secure and auditable access to enterprise data on critical devices, anytime, anywhere. Profiled in Gartner’s Hype Cycle for Storage Technologies, 2012, Datacastle RED is available through a global network of partners. To learn more about Datacastle RED, visit http://www.datacastlered.com, follow on Twitter @Datacastle, or call 425.996.9684.

Media Contact
Karen Sumner
media@datacastlered.com
Phone: +1 425 996 9684, ext 704

– See more at: http://www.datacastlecorp.com/site/press-releases/3272013—datacastle-announces-datacastle-red-v6.html#sthash.7T7dz5Na.dpuf

AdGent Digital CEO, Cam Yuill, offers his thoughts to Skip Brand (CEO, Martini Media) on the advertising and branding opportunities made possible by the rapid increase of content consumption on tablet devices.

http://www.mediapost.com/publications/article/195367/real-time-branding-rich-media-and-the-tablet.html?edition=57643#axzz2NHbHdjBz

And Cam writes further on the effects of new streaming channels and the effectiveness and measurement of advertising through those channels.

http://pandodaily.com/2013/03/12/nielsens-evolution-and-the-coming-of-the-ad-buy-structure-shake-up/

The ThreatMetrix Cybercrime Defender Platform was Honored in the Most Innovative Security Product (Software) of the Year Category

San Jose, CA – March 5, 2013 – ThreatMetrix™, the fastest-growing provider of integrated cybercrime prevention solutions, today announced that Info Security Products Guide, the industry’s leading information security research and advisory guide, has named the ThreatMetrix Cybercrime Defender Platform a Bronze winner of the 2013 Global Excellence Awards in Most Innovative Security Product (Software) of the Year category. The security industry celebrated its 9^th Annual 2013 Global Excellence Awards in San Francisco by honoring excellence in every facet of the industry including products, people behind the successes and best companies.

ThreatMetrix’s leading cybercrime prevention solution – the ThreatMetrix™ Cybercrime Prevention Platform – protects more than 1,500 customers and 8,500 websites from account takeover, payment fraud and fraudulent new registrations in markets including e-commerce, financial services, social networking, government, insurance and enterprise. ThreatMetrix is the first company to combine sophisticated malware detection and advanced device identification technologies in a single platform delivered from the cloud and backed by a global network of shared intelligence.

“Recognition by the Info Security Products Guide further validates the ThreatMetrix Cybercrime Defender Platform as one of the most advanced cybersecurity solutions on the market,” said Reed Taussig, president and CEO, ThreatMetrix. “This industry honor is the greatest endorsement to the fact that ThreatMetrix is ahead of the curve when it comes to solutions that provide the highest security and protection against cybercriminals.”

About Info Security Products Guide

Info Security Products Guide sponsors leading conferences and expos worldwide and plays a vital role in keeping end-users informed of the choices they can make when it comes to protecting their digital resources. It is written expressly for those who are adamant on staying informed of security threats and the preventive measure they can take. You will discover a wealth of information in this guide including tomorrow’s technology today, best deployment scenarios, people and technologies shaping info security and market research that facilitate in making the most pertinent security decisions. The Info Security Products Guide Awards recognize and honor excellence in all areas of information security. To learn more, visit www.infosecurityproductsguide.com and stay secured.

About ThreatMetrix

ThreatMetrix is the fastest-growing provider of integrated cybercrime prevention solutions. The ThreatMetrix™ Cybercrime Defender Platform helps companies protect customer data and secure transactions against fraud, malware, data breaches, as well as man-in-the browser (MitB) and Trojan attacks. The platform consists of advanced cybersecurity technologies, including TrustDefender™ ID, which is cloud-based, real-time device identification, malware protection with TrustDefender™ Cloud and TrustDefender™ Client, as well as TrustDefender™ Mobile for smartphone applications.

Recently named to the Wall Street Journal’s “Next Big Thing” listing of the top 50 start-ups in the U.S., the company serves a rapidly growing global customer base across a variety of industries, including financial services, e-commerce, payments, social networks, government, and insurance. For more information, visit www.threatmetrix.com or call 1-408-200-5755.

© 2013 ThreatMetrix. All rights reserved. ThreatMetrix, TrustDefender ID, TrustDefender Cloud, TrustDefender Mobile, TrustDefender Client, the ThreatMetrix Cybercrime Defender Platform, ThreatMetrix Labs, and the ThreatMetrix logo are trademarks or registered trademarks of ThreatMetrix in the United States and other countries. All other brand, service or product names are trademarks or registered trademarks of their respective companies or owners.

Mobile World Congress is, for many in the mobile community, a pivotal point in the business calendar.  There are always a number of dominant themes at the show and this year Small Cells, in all their various guises, stepped up into the mainstream.

Mesaplexx, a pioneer and innovator in radio filter technology, has created a great summary of the Small Cell landscape and the technology implications that help mobile operators avoid the ever-present capacity crunch.  If you’re interested in understanding this landscape, take a look at the white paper on Mesaplexx web site titled “Active Antennas and Small Cells – Why Filters Matter”.  Highly recommended.

Datacastle Corporation Vice President, Phil Evans, shares his thoughts on the challenges of selecting a cloud provider, and most importantly on the key consideration of security policy.

http://www.techbubbles.co.uk/blog/the-buck-stops-with-you-advice-when-selecting-a-cloud-provider/#more-2994

AdGent Digital CEO offers his thoughts on live streaming of the Super Bowl to tablet devices….

http://venturebeat.com/2013/02/04/cbs-super-bowl-stream/

….and joins a panel of ad industry experts to critique the 2013 class of Super Bowl ads

http://www.hlntv.com/article/2013/02/04/super-bowl-commercials-best-worst-panel-reviews

The office, home to much of Mesaplexx’s intense research and development has moved to enable the set up of a new, dedicated R&D zone, to keep pace with the company’s rapid innovations and aggressive development plans.

Brisbane’s West End district, in the city suburbs, is one of the city’s oldest districts, close to both the University of Queensland and Griffith University, which, along with a strong café culture, brings a diverse and exciting buzz to the area. In turn, this has led a number of startups to choose the area as the location for new and innovative businesses.

Mesaplexx is an innovative start-up company that develops a compact, cool running, high performance filter technology called xCube™. This revolutionary radio filter technology, available for license to mobile equipment vendors, has the capability to radically improve the performance of active antenna systems, carrier grade small cells and compact radio systems, enabling increases in network capacity of up to 65 per cent.

Mesaplexx’s CEO, Mark Bole, commented: “As a venture-backed business focused on delivering truly new and innovative radio filters, it’s fundamental we give our development team the space they need to continue to develop our xCube™ technologies. Our new West End facility not only meets those requirements, but also gives our team a great creative environment of like-minded businesses and individuals to help continue to foster Mesaplexx’s pioneering spirit.”

Mesaplexx’s new address from 28 January, 2013 is:

1st Floor
31 Kurilpa Street
West End
Brisbane
Queensland 4101
Australia

All phone and fax numbers remain unchanged.

The following thoughts from an article by Mark Bole CEO of Talu Investee, Mesaplexx Pty Ltd.  The time is right for disruptive radio filter technology…..

Delivering LTE Coverage and Capacity Gains –

Why Radio Filters Matter

Unprecedented growth in mobile data traffic continues to increase expectations on LTE technology. The pressure is on the operator and supporting vendor community to maximise spectrum efficiency to recoup substantial financial investment and sustain profitability. However, few industry experts expect LTE to carry the data burden in isolation; with many pointing to a collaboration of supporting technologies and techniques, to drive spectral efficiency and maximise network coverage and capacity to meet rising demand.

Active antenna systems (AAS), small cells and other compact radio systems are good examples of these supporting technologies. All are focused on generating additional network coverage and capacity and targeting it towards congested areas of the network. These technologies will become commonplace across next generation networks as part of a heterogeneous network layer.

Given the complexities of next generation network architectures, technologies such as AAS and carrier grade small cells must overcome some technical challenges if they are to reach their full potential. This means removing some of the existing limitations that stem from their existing radio components, and in particular, their radio filters.

Radio filters critical in achieving spectral efficiency

All filters share the same purpose and function – driving spectral efficiency. In the radio access node or base station, the filter selects which signals, in which band, reach the radio receiver, whilst rejecting unwanted frequencies. They achieve this by enabling radio systems to share the same spectrum within the same geographic area. Filters enable mobile operators to partition available spectrum and reduce the need for guard bands to be used to protect against interference caused by adjacent bands. By achieving this, and by blocking spectrum at the band boundaries, filters can maintain a greater number of channels in the band, thus maximising spectrum usage.

Three key challenges facing filter design – size, weight and performance

Equipment vendors are striving to improve the performance of their radio systems whilst making them smaller, lighter and more efficient. Other system components are being successfully miniaturised but infrastructure vendors continue to struggle when it comes to effectively shrinking radio filters. This is a significant obstacle in creating system architectures that meet the needs of the market. This is especially true given that the filters may have to offset any deficiencies caused by the miniaturisation of the other radio components.

Existing filters in AAS and small cells are too large and too heavy. AAS require multiple transceivers to facilitate advanced beam steering techniques and support multiple network technologies on multiple bands (multimode).  This means several filters need locating in the antenna housing, and to achieve this without increasing the overall size and weight of the antennas, they need to be made smaller and lighter. It is also critical that filters do not absorb too much signal power. Doing so increases loss and weakens critical signal strength while generating too much heat. Many of these challenges also apply to small cells, limiting performance, coverage and capacity.

 A breakthrough in radio filter design

The challenge of effective filter miniaturisation has now been overcome. A new compact, cool running, low loss, high isolation filter has now been developed that improves sensitivity and handles much more power than existing technologies. This filter uses multimode resonators, joined together by sophisticated coupling techniques to optimise performance. In fact, these coupling techniques effectively enable the re-use of the same resonator many times.  This dramatically reduces the size of the filter.

Increasing capacity and coverage

The technology will enable operators to enjoy significant capacity improvements. This is achieved by reducing the insertion loss of filters and duplexers, reducing interference and improving the signal to noise ratio. By reducing insertion loss, the filter also improves network coverage by maximising the power amplifier throughput radiated from the base station, increasing the downlink range. It also improves the sensitivity of the system and the maximum range at which a mobile signal can be received and the range at which a device can be used. Handsets will also be able to negotiate a higher throughput at any given range or be able to reduce their transmitted power, thereby extending battery life. This enables better signal strength across wider distances, reducing the number of small cells and macro base stations required.

Power – delivering more with less

Conventional compact filter technologies are often unable to handle more than a few watts of power. This is unsuitable for a significant proportion of cellular networks, including many carrier grade small cells. However, increasing the amount of power causes unwanted heat within the system. This heat can limit overall performance and be expensive to remove. The latest filter technology is capable of reducing this heat by up to 50 per cent – it dissipates a much lower proportion of its input power (just 20 per cent) as heat. This not only leads to an increase in base station capacity but also increases power handling capability and reduces the cost and complexity of dissipating heat. By wasting less of the input power, more power is transmitted in the network. This enables power amplifiers to operate more efficiently, enabling cleaner, greener and more efficient networks and devices.

The ability to successfully miniaturise radio filters has significant implications for the vendor and operator community. The commercial reality at present is that existing radio systems are suffering from a variety of issues that can all be traced back to the performance of the filter. Some face heat challenges, while others are struggling with power output or achieving true multi-band capability. New filter innovation, such as xCube™ from Mesaplexx, enables network vendors to achieve the best possible network architecture by simultaneously solving a variety of challenges. The benefits include increased network coverage or capacity, improving power handling, enhancing sensitivity, reducing heat, lowering power usage, enabling multiband capability and delivering lighter, more environmentally friendly systems. These filters give the mobile industry real cause for optimism.

San Jose based internet threat company, Threatmetrix, has been recognised for its continued stellar presence in the online secutiry domain.

http://www.businessinsider.com/15-most-important-security-startups-2013-1?op=1

AdGent Digital CEO, Cam Yuill, delves into the world of publishers, content subscriptions, and HTML5.

http://www.huffingtonpost.com/cameron-yuill/why-publishers-should-hat_b_2457882.html

Datacastle Corporation Vice President, Craig Blessing, talks with Microsoft TechNet Radio about the use of Microsoft Azure to Protent Business Data.

http://channel9.msdn.com/Shows/TechNet+Radio/TechNet-Radio-Cloud-Innovators–How-Datacastle-uses-Windows-Azure-to-Protect-Business-Data

 Acquisition of TrustDefender, Successful Funding Round and Key Additions to the Management Team Contributed to ThreatMetrix’s Exponential Growth

San Jose, CA – January 8, 2013 – ThreatMetrix™, the fastest-growing provider of integrated cybercrime prevention solutions, today announced its exponential growth in 2012 highlighted by the acquisition of TrustDefender, record revenue, billings and transaction volume, and the addition of hundreds of new customers.

“The acquisition and successful integration of TrustDefender kicked off our most impressive year of growth to date,” said Reed Taussig, president and CEO, ThreatMetrix. “We’ve now delivered 16 consecutive quarters of growth in customer billings. We look forward to another exceptional year protecting our customers from fraud, malware and the global threat of cyberterrorism in 2013.”

ThreatMetrix made significant advances in several key areas in 2012, including:

•        Acquired TrustDefender: ThreatMetrix acquired TrustDefender, a leader of secure browsing technology, to stop man-in-the-browser (MitB) attacks and prevent malware attacks for ThreatMetrix’s growing customer base.

•        Secured New Customers: The company added more than 500 new customers, both directly and in conjunction with its extensive partner channel in 2012; the average new account value of these customers was up 50 percent over 2011.

•        Expanded Presence and Marketshare in Financial Services:  Customer billings and revenues for financial services increased from 20 percent of total contribution to more than 40 percent of total contribution in 2012. ThreatMetrix expects that the financial services market will contribute more than 60 percent of revenues in 2013.

•        Experienced Record Transaction Volume: In 2012, ThreatMetrix experienced 500 percent year-over-year transaction volume growth.

•        Achieved Record Recurring Revenue: The company’s recurring customer revenue in 2012 was 300 percent what they were in 2011, which is a testament to the success ThreatMetrix customers are experiencing with its products.

•        Released New Products and Features: Following the acquisition of TrustDefender, ThreatMetrix released the ThreatMetrix Cybercrime Defender Platform, which helps companies protect customer data and secure against fraud, malware, data breaches, MitB and Trojan attacks. The platform consists of advanced cybersecurity technologies, including TrustDefender™ ID, which is cloud-based, real-time device identification, malware protection with TrustDefender™ Cloud and TrustDefender™ Client, as well as TrustDefender™ Mobile for smartphone applications. In August, ThreatMetrix updated the platform to become the only solution on the market that provides virtual private network (VPN) and phishing detection with advanced device identification and malware protection to combat cybercriminals.

•        Closed Series D Funding: ThreatMetrix secured $18 million in a Series D financing round led by August Capital. ThreatMetrix’s existing investors – Tenaya Capital, US Venture Partners and CM Capital – also participated in the investment.

•        Hired Strategic Management: Frank Teruel joined as vice president of finance and CFO and John Kirst joined as senior vice president of field operations. Andreas Baumhof, executive director, CEO and co-founder of TrustDefender, assumed the role of senior vice president of engineering and chief technology officer.

•        Launched ThreatMetrix Labs: ThreatMetrix launched ThreatMetrix Labs in February, which generates in-depth reports on the latest capabilities of malware that targets financial institutions, merchants and online businesses.

•        Granted Two New U.S. Patents: ThreatMetrix was granted two new patents by the United States Patent Office to enhance cybercrime detection and prevention. For several years, patented technology and ongoing product enhancements have enabled ThreatMetrix to lead the industry with continuous innovation in cybercrime detection and prevention solutions.

•        Hosted 2012 Fraud Fighters Summit: ThreatMetrix hosted its second annual Fraud Fighters Summit in October, uniting more than 200 industry leaders in the fight against cybercrime.

•        Named to Wall Street Journal’s “Next Big Thing” List: In October, ThreatMetrix was named to the Wall Street Journal’s “Next Big Thing” list of the top 50 start-ups in the U.S. The third-annual ranking of venture-capital-backed U.S. companies was compiled from a list of more than 5,900 candidates.

“Cybercriminals have the financial services value chain in their crosshairs, and the threats to government and insurance institutions are rapidly mounting as well,” said Julie Conroy, research director, Aite Group. “Unique strains of malware topped 100 million in 2012, and the trajectory is growing at a frightening pace.  It is incumbent upon financial institutions, merchants, and government entities to protect both themselves and their customers with a robust approach that includes multiple, complementary layers of security.  As we’ve seen time and time again, it’s all too easy for fraudsters to circumvent any single point solution.”

Bayer HealthCare Introduces ResultixTM, a New Tick Killing Solution for Dogs and Cats

• Pet owners and veterinarians can kill ticks without the ick!

Shawnee, Kans, November 29, 2012 – Today, Bayer HealthCare LLC Animal Health
Division made it easy to kill ticks on dogs and cats with Resultix, a new, simple spray-on
formula that kills attached or crawling ticks. Bayer HealthCare debuted Resultix at the
opening of BarkWorld Expo, a pet social media conference in Atlanta, Ga on October 26.

Resultix provides an effective way to kill ticks and can be used as often as needed. Just
two sprays of Resultix will dissolve the outer wax layer that covers the hard shell (cuticle)
of the tick, resulting in uncontrollable water loss and death of the tick. The tick will be
dead within three hours; it may either fall off of the dog or cat, or be immobile when
removed.

Resultix, available in an easy to transport 20 mL bottle, will be sold through veterinary
clinics, pet specialty stores and online retailers.

Ticks are common parasites that feed on dogs and cats alike and may infest pets in very
large numbers.

“A tick can cause serious problems for pets and dealing with tick infestations can be
stressful for both pet owners and their pets,” said Cristiano von Simson, DVM, MBA,
Director of Veterinary Technical Services at Bayer HealthCare LLC, Animal Health
Division, North America. “Resultix provides a convenient and easy to apply alternative to
traditional tick removal for pet owners and veterinarians who spot one or more ticks on a
dog or cat.”

Bayer HealthCare collaborated with Piedmont Pharmaceuticals to bring Resultix to
market.

Bayer HealthCare Introduces ResultixTM, a New Tick Killing Solution
for Dogs and Cats

“We are very pleased to celebrate the first product launch resulting from our partnership
with Bayer HealthCare,” said Roland Johnson, Chairman and CEO, Piedmont
Pharmaceuticals. “The technology in Resultix created by Piedmont truly makes it an
effective tick killing product.”

For more information on Resultix, visit killthetick.com, where you can also learn how to
join the PetParents.com community for access to helpful pet tips and resources.

About Bayer HealthCare

The Bayer Group is a global enterprise with core competencies in the fields of health
care, nutrition and high-tech materials. Bayer HealthCare, a subgroup of Bayer AG with
annual sales of EUR 17.2 billion (2011), is one of the world’s leading, innovative
companies in the healthcare and medical products industry and is based in Leverkusen,
Germany. The company combines the global activities of the Animal Health, Consumer
Care, Medical Care and Pharmaceuticals divisions. Bayer HealthCare’s aim is to
discover, develop, manufacture and market products that will improve human and animal
health worldwide. Bayer HealthCare has a global workforce of 55,700 employees (Dec
31, 2011) and is represented in more than 100 countries. Find more information at
www.bayerhealthcare.com.